top of page

Univercells presents its revolutionary biomanufacturing platform: Nevoline system

On Friday January 11th 2019, Univercells presented its revolutionary biomanufacturing platform - the Nevoline system. A facility designed with 4 NevoLine is able to produce 50M doses of polio vaccines at less than $0.30/dose.

In December 2016, a consortium led by Belgium biomanufacturing technology firm Univercells received a $12 million (€10.4 million) grant from the Bill & Melinda Gates Foundation to develop a low-cost vaccine manufacturing platform. The consortium also involves Batavia Biosciences which has developed the polio manufacturing process and Natrix Separations for the purification membrane.

Two years on and a $4 million grant extension has been awarded to Univercells and Batavia Biosciences to scale-up the firm’s NevoLine system for the production of inactivated polio vaccine (sIPV).

“This challenging two-year project aimed at delivering a new manufacturing system to drastically decrease cost, footprint and time to market for vaccine manufacturers, and we are pleased to have met these goals,” said Univercells CEO Hugues Bultot.


bottom of page